Provided by Tiger Fintech (Singapore) Pte. Ltd.

Outlook Therapeutics, Inc.

1.31
+0.11009.17%
Post-market: 1.340.0300+2.29%19:30 EDT
Volume:3.20M
Turnover:4.29M
Market Cap:58.19M
PE:-0.87
High:1.41
Open:1.22
Low:1.22
Close:1.20
52wk High:6.98
52wk Low:0.7900
Shares:44.42M
Float Shares:24.35M
Volume Ratio:1.40
T/O Rate:13.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5016
EPS(LYR):-4.0632
ROE:-3.65%
ROA:-130.65%
PB:-1.56
PE(LYR):-0.32

Loading ...

Outlook Therapeutics Shares Sink Pre-Bell After FDA Declines Approval for Wet AMD Drug Candidate

MT Newswires Live
·
Aug 28

Outlook Therapeutics Shares Down 60.4% Premarket After US FDA Declines to Approve Its Drug for Eye Condition

THOMSON REUTERS
·
Aug 28

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Reuters
·
Aug 28

Outlook Therapeutics Inc - FDA Notes Ons-5010 Did Not Meet Efficacy Endpoint

THOMSON REUTERS
·
Aug 28

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™ (Bevacizumab-Vikg) for the Treatment of Wet Amd

THOMSON REUTERS
·
Aug 28

Outlook Therapeutics: FDA Advised It Is Recommended Confirmatory Evidence of Efficacy Be Submitted to Support Application for Ons-5010

THOMSON REUTERS
·
Aug 28

Outlook Therapeutics Inc - Crl Cites Lack of Evidence of Effectiveness

THOMSON REUTERS
·
Aug 28

Outlook Therapeutics Q3 Adj. EPS $(0.44) Misses $(0.39) Estimate, Sales $1.505M Miss $1.663M Estimate

Benzinga
·
Aug 14

BRIEF-Outlook Therapeutics Q3 EPS USD -0.55

Reuters
·
Aug 14

Outlook Therapeutics Inc - FDA Pdufa Goal Date for Ons-5010 Set for August 27, 2025

THOMSON REUTERS
·
Aug 14

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

THOMSON REUTERS
·
Aug 14

Outlook Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
Aug 09

Outlook Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO Robert Jahr

Reuters
·
Jul 10

Press Release: Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Dow Jones
·
Jul 01

BRIEF-Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD

Reuters
·
Jun 10

BRIEF-Outlook Therapeutics Announces Commercial Launch Of Lytenava In Germany And UK For Treatment Of Wet AMD

Reuters
·
Jun 02

BRIEF-Outlook Therapeutics Announces Pricing Of $13.0 Million Public Offering

Reuters
·
May 23

Outlook Therapeutics Plans Share Offering; Stock Declines After Hours

MT Newswires Live
·
May 23

Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Outlook Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview

Reuters
·
May 12